Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease

Namiki Izumi received lecture fees from Gilead Sciences Inc. and AbbVie. Masayuki Kurosaki received lecture fees from Gilead Sciences Inc., AbbVie, Eisai Co., Ltd., Bayer AG, and Otsuka Holdings Co., Ltd. The other authors have no conflicts of interest to declare.